abstract：:Nanotechnology has enabled significant advances in the areas of cancer diagnosis and therapy. The field of drug delivery is a sterling example, with nanoparticles being increasingly used for generating therapeutic formulations of poorly water-soluble, yet potent anticancer drugs. Whereas a number of nanoparticle-drug ...

journal_title：Molecular cancer therapeutics

authors： Bisht S,Feldmann G,Koorstra JB,Mullendore M,Alvarez H,Karikari C,Rudek MA,Lee CK,Maitra A,Maitra A

更新日期：2008-12-01 00:00:00

abstract：:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively kills tumor cells. However, its short half-life, poor delivery, and TRAIL-resistant tumor cells have diminished its clinical efficacy. In this study, we explored whether novel delivery methods will represent new and effective ways to treat gli...

journal_title：Molecular cancer therapeutics

authors： Hingtgen S,Ren X,Terwilliger E,Classon M,Weissleder R,Shah K

更新日期：2008-11-01 00:00:00

abstract：:Imatinib mesylate is a potent, molecularly targeted therapy against the oncogenic tyrosine kinase BCR-ABL. Although imatinib mesylate has considerable efficacy against chronic myeloid leukemia (CML), advanced-stage CML patients frequently become refractory to this agent. The bone marrow is the predominant microenviron...

journal_title：Molecular cancer therapeutics

authors： Bewry NN,Nair RR,Emmons MF,Boulware D,Pinilla-Ibarz J,Hazlehurst LA

更新日期：2008-10-01 00:00:00

abstract：:ABT-263 is a potent, orally bioavailable inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-x(L), and Bcl-w, which is currently in phase I clinical trials. Previous work has shown that this compound has low nanomolar cell-killing activity in a variety of lymphoma and leukemia cell lines, many of which over...

journal_title：Molecular cancer therapeutics

authors： Ackler S,Xiao Y,Mitten MJ,Foster K,Oleksijew A,Refici M,Schlessinger S,Wang B,Chemburkar SR,Bauch J,Tse C,Frost DJ,Fesik SW,Rosenberg SH,Elmore SW,Shoemaker AR

更新日期：2008-10-01 00:00:00

abstract：:The therapeutic efficiency of anticancer nucleoside analogues (NA) strongly depends on their intracellular accumulation and conversion into 5'-triphosphates. Because active NATP cannot be directly administrated due to instability, we present here a strategy of nanoencapsulation of these active drugs for efficient deli...

journal_title：Molecular cancer therapeutics

authors： Galmarini CM,Warren G,Kohli E,Zeman A,Mitin A,Vinogradov SV

更新日期：2008-10-01 00:00:00

abstract：:Penta-1,2,3,4,6-O-galloyl-beta-D-glucose (PGG) is a naturally occurring gallotannin from some Oriental herbs. Several cell culture studies suggested a potential for PGG as a novel agent for the chemoprevention and treatment of cancer. Here, we investigated the cell death signaling mechanisms induced by PGG in human pr...

journal_title：Molecular cancer therapeutics

authors： Hu H,Lee HJ,Jiang C,Zhang J,Wang L,Zhao Y,Xiang Q,Lee EO,Kim SH,Lü J

更新日期：2008-09-01 00:00:00

abstract：:Ras signaling can be modulated by the scaffolding activity of kinase suppressor of Ras-1 (KSR-1) and by the hKSR-2 protein, resulting in diverse phenotypic outcomes. The mitogen-activated protein kinase cascade downstream from Ras and KSRs includes Raf-1 and extracellular signal-regulated kinase 1/2 kinases, known to ...

journal_title：Molecular cancer therapeutics

authors： Wang X,Patel R,Studzinski GP

更新日期：2008-09-01 00:00:00

abstract：:At later stages of tumor progression, epithelial carcinogenesis is associated with transition to a mesenchymal phenotype, which may contribute to the more aggressive properties of cancer cells and may be stimulated by growth factors such as epidermal growth factor and transforming growth factor-beta. Previously, we fo...

journal_title：Molecular cancer therapeutics

authors： Paccione RJ,Miyazaki H,Patel V,Waseem A,Gutkind JS,Zehner ZE,Yeudall WA

更新日期：2008-09-01 00:00:00

abstract：:Aberrant DNA methylation patterns play an important role in the pathogenesis of hematologic malignancies. The DNA methyltransferase inhibitors azacytidine and decitabine have shown significant clinical benefits in the treatment of myelodysplastic syndrome (MDS), but their precise mode of action remains to be establish...

journal_title：Molecular cancer therapeutics

authors： Stresemann C,Bokelmann I,Mahlknecht U,Lyko F

更新日期：2008-09-01 00:00:00

abstract：:Recent studies have shown that naturally occurring compounds can enhance the efficacy of chemotherapeutic drugs. The objectives of this study were to investigate the molecular mechanisms by which diallyl trisulfide (DATS) enhanced the therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand (TR...

journal_title：Molecular cancer therapeutics

authors： Shankar S,Chen Q,Ganapathy S,Singh KP,Srivastava RK

更新日期：2008-08-01 00:00:00

abstract：:The tumor suppressor protein p53 is a potent inducer of apoptosis in transformed cells. Hdm2 is an ubiquitin ligase (E3) that acts as a major regulator of p53 by promoting its ubiquitylation and proteasomal degradation. For this reason, inhibiting the E3 activity of Hdm2 has been proposed as a therapeutic approach for...

journal_title：Molecular cancer therapeutics

authors： Kitagaki J,Agama KK,Pommier Y,Yang Y,Weissman AM

更新日期：2008-08-01 00:00:00

abstract：:Expression of fatty acid synthase (FASN), the key enzyme in de novo synthesis of long-chain fatty acids, is normally low but increases in cancer. Consequently, FASN is a novel target for cancer therapy. However, because FASN inhibitors can lead to tumor stasis rather than shrinkage, noninvasive methods for assessing F...

journal_title：Molecular cancer therapeutics

authors： Ross J,Najjar AM,Sankaranarayanapillai M,Tong WP,Kaluarachchi K,Ronen SM

更新日期：2008-08-01 00:00:00

abstract：:Thalidomide is considered to be a potent antiangiogenic and immunomodulatory drug for cancer therapy. Earlier clinical studies have found that patients responding to this drug often had high plasma levels of basic fibroblast growth factor (bFGF). This cytokine is a proangiogenic factor overexpressed in many tumors and...

journal_title：Molecular cancer therapeutics

authors： Mei SC,Wu RT

更新日期：2008-08-01 00:00:00

abstract：:Activation of translation initiation is essential for the malignant phenotype and is emerging as a potential therapeutic target. Translation is regulated by the expression of translation initiation factor 4E (eIF4E) as well as the interaction of eIF4E with eIF4E-binding proteins (e.g., 4E-BP1). Rapamycin inhibits tran...

journal_title：Molecular cancer therapeutics

authors： Soni A,Akcakanat A,Singh G,Luyimbazi D,Zheng Y,Kim D,Gonzalez-Angulo A,Meric-Bernstam F

更新日期：2008-07-01 00:00:00

abstract：:The majority of patients with HER2-overexpressing metastatic breast cancer who initially respond to the HER2-targeted antibody trastuzumab show disease progression within 1 year. The identification of novel agents that effectively inhibit survival of cancer cells that have progressed on trastuzumab is critical for imp...

journal_title：Molecular cancer therapeutics

authors： Rowe DL,Ozbay T,Bender LM,Nahta R

更新日期：2008-07-01 00:00:00

abstract：:Eribulin (E7389), a synthetic analogue of halichondrin B in phase III clinical trials for breast cancer, binds to tubulin and microtubules. At low concentrations, it suppresses the growth phase of microtubule dynamic instability in interphase cells, arrests mitosis, and induces apoptosis, suggesting that suppression o...

journal_title：Molecular cancer therapeutics

authors： Okouneva T,Azarenko O,Wilson L,Littlefield BA,Jordan MA

更新日期：2008-07-01 00:00:00

abstract：:Breast cancer resistance to the antiestrogens tamoxifen (OHT) and fulvestrant is accompanied by alterations in both estrogen-dependent and estrogen-independent signaling pathways. Consequently, effective inhibition of both pathways may be necessary to block proliferation of antiestrogen-resistant breast cancer cells. ...

journal_title：Molecular cancer therapeutics

authors： Long X,Fan M,Bigsby RM,Nephew KP

更新日期：2008-07-01 00:00:00

abstract：:Targeting death receptor-mediated apoptosis has emerged as an effective strategy for cancer therapy. However, certain types of cancer cells are intrinsically resistant to death receptor-mediated apoptosis. In an effort to identify agents that can sensitize cancer cells to death receptor-induced apoptosis, we have iden...

journal_title：Molecular cancer therapeutics

authors： Raja SM,Chen S,Yue P,Acker TM,Lefkove B,Arbiser JL,Khuri FR,Sun SY

更新日期：2008-07-01 00:00:00

abstract：:The oncoprotein Eps8 facilitates proliferation in fibroblasts and colon cancer cells. However, its role in human cervical cancer is unclear. By immunohistochemical staining and Western blotting, aberrant Eps8 expression was observed in cervical carcinoma compared with normal cervical epithelial cells. Clinicopathologi...

journal_title：Molecular cancer therapeutics

authors： Chen YJ,Shen MR,Chen YJ,Maa MC,Leu TH

更新日期：2008-06-01 00:00:00

abstract：:Histone deacetylase inhibitors have emerged as promising anticancer drugs. Using an unbiased ultrahigh throughput screening system, a novel mercaptoketone-based histone deacetylase inhibitor series was identified that was optimized to the lead compound, KD5170. KD5170 inhibited the proliferation of myeloma cell lines ...

journal_title：Molecular cancer therapeutics

authors： Feng R,Ma H,Hassig CA,Payne JE,Smith ND,Mapara MY,Hager JH,Lentzsch S

更新日期：2008-06-01 00:00:00

abstract：:Conditionally replicating adenoviruses (CRAd) can replicate specifically in cancer cells and lyse them. The CRAds were widely used in the preclinical and clinical studies of cancer therapy. We hypothesize that more precisely regulated replication of CRAds may further improve the vector safety profile and enhance its a...

journal_title：Molecular cancer therapeutics

authors： Wang X,Su C,Cao H,Li K,Chen J,Jiang L,Zhang Q,Wu X,Jia X,Liu Y,Wang W,Liu X,Wu M,Qian Q

更新日期：2008-06-01 00:00:00

abstract：:AMAD, an emodin azide methyl anthraquinone derivative, was extracted from the nature giant knotweed rhizome of traditional Chinese herbs. Here, we investigated the anticancer activities and signaling pathways implicated in AMAD-induced apoptosis in human breast cancer cell lines MDA-MB-453 and human lung adenocarcinom...

journal_title：Molecular cancer therapeutics

authors： Yan Y,Su X,Liang Y,Zhang J,Shi C,Lu Y,Gu L,Fu L

更新日期：2008-06-01 00:00:00

abstract：:Histopathologic grading of astrocytic tumors based on current WHO criteria offers a valuable but simplified representation of oncologic reality and is often insufficient to predict clinical outcome. In this study, we report a new astrocytic tumor microarray gene expression data set (n = 65). We have used a simple arti...

journal_title：Molecular cancer therapeutics

authors： Petalidis LP,Oulas A,Backlund M,Wayland MT,Liu L,Plant K,Happerfield L,Freeman TC,Poirazi P,Collins VP

更新日期：2008-05-01 00:00:00

abstract：:We compared the antitumor activities of the multitargeted tyrosine kinase inhibitors imatinib, sorafenib, and sunitinib to determine which inhibitor is best suited to be used for the treatment of acute myelogenous leukemia (AML). In nine human AML cell lines, sorafenib and sunitinib were more potent inhibitors of cell...

journal_title：Molecular cancer therapeutics

authors： Hu S,Niu H,Minkin P,Orwick S,Shimada A,Inaba H,Dahl GV,Rubnitz J,Baker SD

更新日期：2008-05-01 00:00:00

abstract：:Plasminogen activator inhibitor-1 (PAI-1) is an important endogenous inhibitor of urokinase-type plasminogen activator. Its action in tumor angiogenesis is complicated, varying with experimental setting and its cellular origin. To further understand the mechanism of the effect of PAI-1 on tumor angiogenesis, especiall...

journal_title：Molecular cancer therapeutics

authors： Chen SC,Henry DO,Reczek PR,Wong MK

更新日期：2008-05-01 00:00:00

abstract：:Genital human papillomavirus (HPV) infection is the primary cause of cervical cancer in women. Although the HPV recombinant L1 protein was recently licensed as an available vaccine, it has numerous shortcomings. New vaccination strategies should be considered. To enable the design of a prophylactic and therapeutic low...

journal_title：Molecular cancer therapeutics

authors： Bian T,Wang Y,Lu Z,Ye Z,Zhao L,Ren J,Zhang H,Ruan L,Tian H

更新日期：2008-05-01 00:00:00

abstract：:The ability of the epidermal growth factor receptor inhibitor gefitinib (Iressa) to prevent/treat methylnitrosourea (MNU)-induced mammary cancers and to modulate biomarkers in female Sprague-Dawley rats was examined. Rats were given a single dose of MNU (75 mg/kg body weight) at 50 days of age. In the prevention studi...

journal_title：Molecular cancer therapeutics

authors： Lubet RA,Szabo E,Christov K,Bode AM,Ericson ME,Steele VE,Juliana MM,Grubbs CJ

更新日期：2008-04-01 00:00:00

abstract：:Nonselective inhibitors of human histone deacetylases (HDAC) are known to have antitumor activity in mice in vivo, and several of them are under clinical investigation. The first of these, Vorinostat (SAHA), has been approved for treatment of cutaneous T-cell lymphoma. Questions remain concerning which HDAC isotype(s)...

journal_title：Molecular cancer therapeutics

authors： Fournel M,Bonfils C,Hou Y,Yan PT,Trachy-Bourget MC,Kalita A,Liu J,Lu AH,Zhou NZ,Robert MF,Gillespie J,Wang JJ,Ste-Croix H,Rahil J,Lefebvre S,Moradei O,Delorme D,Macleod AR,Besterman JM,Li Z

更新日期：2008-04-01 00:00:00

abstract：:Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor (EGFR) kinase domain tend to respond well to the tyrosine kinase inhibitors, gefitinib and erlotinib. However, following clinical response, these patients typically relapse within a year of treatment...

journal_title：Molecular cancer therapeutics

authors： Godin-Heymann N,Ulkus L,Brannigan BW,McDermott U,Lamb J,Maheswaran S,Settleman J,Haber DA

更新日期：2008-04-01 00:00:00

abstract：:NAG-1 (nonsteroidal anti-inflammatory drug-activated gene), a member of the transforming growth factor-beta superfamily, is involved in many cellular processes, such as inflammation, apoptosis/survival, and tumorigenesis. Vitamin E succinate (VES) is the succinate derivative of alpha-tocopherol and has antitumorigenic...

journal_title：Molecular cancer therapeutics

authors： Shim M,Eling TE

更新日期：2008-04-01 00:00:00

abstract：:High Mycoplasma infection in gastric cancer tissues suggests a possible association between Mycoplasma infection and tumorigenesis. By using human gastric cancer cells AGS and mouse melanoma cells B16F10 stably expressing p37, the major immunogen of Mycoplasma hyorhinis, we found that p37 enhanced cell motility, migra...

journal_title：Molecular cancer therapeutics

authors： Gong M,Meng L,Jiang B,Zhang J,Yang H,Wu J,Shou C

更新日期：2008-03-01 00:00:00

abstract：:Gemcitabine shows a marked antitumor effect as a result of its cytotoxic action toward proliferative cells. In this article, we aim to investigate the potential antitumor and antiangiogenic effect of gemcitabine following a metronomic schedule that involves the regular administration of cytotoxic drugs at doses lower ...

journal_title：Molecular cancer therapeutics

authors： Laquente B,Lacasa C,Ginestà MM,Casanovas O,Figueras A,Galán M,Ribas IG,Germà JR,Capellà G,Viñals F

更新日期：2008-03-01 00:00:00

abstract：:Novel molecules are constantly being discovered and developed to find better means of managing debilitating and fatal diseases, which include cancer in its multiple forms. Among these molecules, and as a direct consequence of a better understanding of the molecular basis of diseases, are those falling within the class...

journal_title：Molecular cancer therapeutics

authors： Dass CR,Choong PF,Khachigian LM

更新日期：2008-02-01 00:00:00

abstract：:In the present work, we have investigated the antitumor activity of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on aggressive small cell lung cancer. NBDHEX not only is cytotoxic toward the parental small cell lung cancer H69 cell line (LC(50) of 2.3 +/- 0.6 micromol/L) but also overcomes the multidrug re...

journal_title：Molecular cancer therapeutics

authors： Filomeni G,Turella P,Dupuis ML,Forini O,Ciriolo MR,Cianfriglia M,Pezzola S,Federici G,Caccuri AM

更新日期：2008-02-01 00:00:00

abstract：:Increasing literature suggests that cell adhesion molecule alpha4beta1 integrin plays a pivotal role in autoimmune diseases and cancer development. Noninvasive visualization of alpha4beta1 integrin in vivo will facilitate the understanding of its involvement in disease progression and development of targeted therapies...

journal_title：Molecular cancer therapeutics

authors： Peng L,Liu R,Andrei M,Xiao W,Lam KS

更新日期：2008-02-01 00:00:00

abstract：:Integrin-linked kinase (ILK) was assesed as a therapeutic target in glioblastoma xenograft models through multiple endpoints including treatment related changes in the tumor microenvironment. Glioblastoma cell lines were tested in vitro for sensitivity toward the small-molecule inhibitors QLT0254 and QLT0267. Cell via...

journal_title：Molecular cancer therapeutics

authors： Edwards LA,Woo J,Huxham LA,Verreault M,Dragowska WH,Chiu G,Rajput A,Kyle AH,Kalra J,Yapp D,Yan H,Minchinton AI,Huntsman D,Daynard T,Waterhouse DN,Thiessen B,Dedhar S,Bally MB

更新日期：2008-01-01 00:00:00

abstract：:Our previous studies have shown that z-guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. We now report a novel response to z-guggulsterone involving the inhibition of angiogenesis in vitro and in vivo. The z-guggu...

journal_title：Molecular cancer therapeutics

authors： Xiao D,Singh SV

更新日期：2008-01-01 00:00:00

abstract：:Molecular profiling of markers involved in the activity of chemotherapeutic agents can shed light on the successes and failures of treatment in patients and can also provide a basis for individualization of therapy. Toward those ends, we have used reverse-phase protein lysate microarrays to evaluate expression of prot...

journal_title：Molecular cancer therapeutics

authors： Stevens EV,Nishizuka S,Antony S,Reimers M,Varma S,Young L,Munson PJ,Weinstein JN,Kohn EC,Pommier Y

更新日期：2008-01-01 00:00:00

abstract：:The present studies have determined whether interactions between the cyclin-dependent kinase inhibitor flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA; vorinostat; Zolinza) occur in breast cancer cells. MDA-MB-231 and MCF7 cells were treated with flavopiridol (25-100 nmol/L) an...

journal_title：Molecular cancer therapeutics

authors： Mitchell C,Park MA,Zhang G,Yacoub A,Curiel DT,Fisher PB,Roberts JD,Grant S,Dent P

更新日期：2007-12-01 00:00:00

abstract：:PHA-739358 is a small-molecule 3-aminopyrazole derivative with strong activity against Aurora kinases and cross-reactivities with some receptor tyrosine kinases relevant for cancer. PHA-739358 inhibits all Aurora kinase family members and shows a dominant Aurora B kinase inhibition-related cellular phenotype and mecha...

journal_title：Molecular cancer therapeutics

authors： Carpinelli P,Ceruti R,Giorgini ML,Cappella P,Gianellini L,Croci V,Degrassi A,Texido G,Rocchetti M,Vianello P,Rusconi L,Storici P,Zugnoni P,Arrigoni C,Soncini C,Alli C,Patton V,Marsiglio A,Ballinari D,Pesenti E,Fan

更新日期：2007-12-01 00:00:00